Shire ADHD drug shows benefits for adult patients

Shire has announced new clinical trial data demonstrating the benefits of its new drug SHP465-306 in treating attention deficit hyperactivity disorder (ADHD) in adults.

Positive topline results have been reported from a four-week efficacy and safety study of SHP465-306 in 275 adults aged 18 to 55 years with ADHD, showing that the drug met its primary endpoints for both dosing options. 

The findings demonstrated the superiority of Shire's new therapy over placebo in ADHD symptom improvement, with both doses showing significant improvements over placebo in enhancing global functioning.

This study adds to a robust database of clinical studies, enrolling more than 1,600 subjects, in the SHP465 clinical development programme. Shire is now planning to file for US approval of the therapy before the end of the year.

Dr Philip Vickers, head of research and development at Shire, said: "We are excited that SHP465, when taking into account the broader clinical development programme and multiple dosing strengths, has the potential to benefit adult patients with ADHD."